Qiming Venture Partners

🔊 Looking back, what Qiming Venture Partners has achieved? Find out more in 60 seconds.

The first working day after the Chinese New Year holiday marked a significant milestone for Qiming Venture Partners' portfolio company DeepWay BEV Truck, as the company successfully delivered 207 heavy trucks across China, setting the tone for a prosperous year ahead. Deliveries were distributed across key regions, including 54 trucks to Chengdu, Sichuan; 46 trucks to Shanghai; 33 trucks to Huanghua, Hebei; 23 trucks to Tangshan, Hebei; 17 trucks to Chongqing; 16 trucks to Taiyuan, Shanxi; and 18 trucks to other regions. These numbers are more than just deliveries—they represent DeepWay's commitment to innovation, quality, and customer satisfaction. #Logistics #HeavyTrucks #Innovation #Transportation #CustomerSuccess #SupplyChain #ChinaManufacturing #QimingPortfolio #QimingTechnologyAndConsumer

In a remote tuberculosis screening site in Kyrgyzstan, healthcare workers are leveraging a portable X-ray machine powered by AI diagnostic technology, developed by Infervision, a Qiming Venture Partners' portfolio company. This advanced AI system analyzes chest X-ray images in real-time, providing results in under 15 seconds and significantly enhancing both the speed and accuracy of screenings. The system can process up to 400 patients daily. To further support local healthcare providers, Infervision has partnered with the UN Development Programme to conduct training sessions, ensuring medical staff are proficient in using the technology. As Infervision's Founder and Chairman, Kuan Chen, shared, "Through our ongoing collaboration with local experts, healthcare professionals in Kyrgyzstan are now fully equipped to utilize this technology effectively." This innovative solution is also being deployed in Uzbekistan, Moldova, South Africa, Zimbabwe, and other countries. Kuan Chen added, "We are committed to continuous product upgrades, harnessing AI to strengthen healthcare systems in these regions in partnership with the UN Development Programme." #AIHealthcare #GlobalHealth #MedicalInnovation #TBScreening #HealthcareTech #QimingPortfolioESG #QimingHealthcare

Nature has recently recognized single-cell microbial analysis as one of the seven technologies to watch in 2025, due to its groundbreaking potential in advancing microbiological research. As a pioneer in microbial single-cell transcriptomic sequencing, M20 Genomics, a portfolio company of Qiming Venture Partners, launched the VITA platform in March 2022. With its exceptional performance and robust commercial applications, the platform is providing invaluable support for microbial functional research at single-cell resolution. By Q4 2024, the VITA platform has already assisted over 200 research teams globally, analyzing more than 7,000 microbial samples — a significant step forward in the field. #MicrobialResearch #SingleCellAnalysis #InnovationInScience #Nature #QimingPortfolio #QimingHealthcare

A pioneering study, led by the First Affiliated Hospital of Xinjiang Medical University and supported by Qiming Venture Partners' portfolio company Shukun Technology, has been published in Cardiovascular Diabetology. This research offers new insights into the early diagnosis and risk assessment of Coronary Artery Disease (CAD). The study included 60 CAD patients who underwent coronary artery bypass surgery and coronary CTA, alongside 60 healthy controls. Using Shukun Technology's CoronaryDoc platform, the team segmented PCAT and extracted radiomic features using Shukun Technology's advanced platform. Gene expression data from fat tissue and serum were quantified using RT-qPCR, immunohistochemistry, and ELISA techniques. The results demonstrated a significant correlation between PCAT radiomic features and gene expression in CAD patients, shedding light on PCAT's role in the disease's progression. These findings suggest that PCAT radiomic features could serve as a valuable, non-invasive indicator for CAD risk assessment. #CardiovascularResearch #CAD #InnovationInHealthcare #MedicalResearch #EarlyDiagnosis #RiskAssessment #DigitalHealth #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/g33jK3cQ

APT Medical (SHSE: 688617), a Qiming Venture Partners' portfolio company, has officially launched the iPass Pro microcatheter. Engineered to meet diverse clinical needs, iPass Pro is available in 1.9F, 2.1F, and 2.6F sizes with working lengths of 135cm and 150cm. Featuring a four-layer shaft design reinforced with a stainless steel braid and coiled structure, it delivers exceptional torque control. The catheter also incorporates a patented octagonal strain relief sheath, enhancing user experience and procedural efficiency. #MedicalInnovation #InterventionalCardiology #Microcatheter #CTOProcedures #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company Qingflow has established its Shandong Operations Center, further accelerating the region's digital transformation. Qingflow has also signed a strategic cooperation agreement with Fareast Credit, Shiyuan Digital Technology, the Shanghai Computer Industry Association, To Youth Information Technology, and the Rizhao Platform Economy Industrial Park. This collaboration aims to build a digital talent center, fostering innovation and driving industrial upgrades. In addition, Qingflow has launched two new systems built on its no-code development platform: the HR Intelligent Management System and the Park Operations Management System. These solutions showcase Qingflow's ability to support complex business needs and highlight the impact of no-code technology in accelerating digital transformation. #DigitalTransformation #Innovation #SmartEnterprise #HRTech #IndustrialUpgrade #QimingPortfolio #QimingTechnologyandConsumer

Hesai Technology (NASDAQ: HSAI), a portfolio company of Qiming Venture Partners, announced a strategic collaboration with Outsight and embotech AG to deliver cutting-edge lidar technology and perception software for Embotech's AVM technology deployed in BMW facilities and known internally at BMW as Automated Driving In-Plant (AFW). This collaboration brings together industry leaders in autonomous driving solutions and sensing technology. "Hesai Technology is proud to partner with Embotech and Outsight to deliver cutting-edge lidar technology for BMW's Automated Vehicle Marshalling (AVM) system," says Dr. David Li, Co-founder and CEO of Hesai Technology. "This state-of-the-art technology demonstrates the high level of precision and safety offered by our lidar and Outsight's perception software for Embotech's autonomous driving solutions. We look forward to continuing our collaboration and bringing this technology to more factories around the world." #Lidar #AutonomousDriving #PerceptionSoftware #AVM #BMW #Automation #SmartManufacturing #Innovation #QimingPortfolio #QimingTechnologyandConsumer Read More: https://lnkd.in/dDD6zfac

At the 2025 Arab International Medical Laboratory Instruments and Equipment Exhibition (Medlab Middle East), Qiming Venture Partners' portfolio company VINNO Ultrasound unveiled its latest ultrasound innovations, including the flagship ULTIMUS 9, the newly launched VINNO R700, R300, and S series, the high-end portable VINNO 10, and the handheld VINNO P and VINNO Q+. The VINNO R700 series, a standout among the latest releases, received strong recognition for its advanced applications in obstetrics, gynecology, and cardiovascular imaging. Powered by the upgraded VLucid2.0 imaging platform, the R700 delivers exceptional image quality, advanced automation, and a suite of diagnostic tools, enabling physicians to achieve greater efficiency and precision in ultrasound diagnostics. #MedlabMiddleEast #Ultrasound #MedicalImaging #HealthcareInnovation #DiagnosticExcellence #MedicalTechnology #Obstetrics #CardiovascularImaging #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company Belief BioMed announced that it has received China's National Medical Products Administration acceptance of an Investigational New Drug (IND) application for BBM-D101, the company's Duchenne Muscular Dystrophy (DMD) gene therapy candidate. This clinical trial is an open label and single-dose clinical study, which was designed to evaluate the safety and efficacy of a single intravenous infusion in DMD patients aged 4-9 years old. Due to engineered capsid, BBM-D101 has a higher efficiency to transduce muscle tissue. Therefore, the proposed clinical dosage is lower than the approved similar adeno-associated virus (AAV) gene therapy products, and BBM-D101 is expected to have good safety. #GeneTherapy #DuchenneMuscularDystrophy #DMD #Biotech #RareDisease #PrecisionMedicine #AAV #ClinicalTrials #NMPA #HealthcareInnovation #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/grEM7QpR